Susan Dimick
Family Medicine · Edmond, OKNPI 1083663611
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,456 of the $28,122 with a category attached, or 69.2%. Amgen accounts for 69.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $8,757 and has fallen 92.3% since, to $672 in 2025. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $232.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Medicure Pharma Inc.$2K
- Kowa Pharmaceuticals America, Inc.$2K
- Novartis$697
- Amarin Pharma, Inc.$565
- Novo Nordisk$540
- plus $3K from 20 others
Across 42 payments — averaging $5423.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ionis Pharmaceuticals, Inc.$101K
- Novartis$87K
- Alnylam Pharmaceuticals Inc.$30K
- Amgen$11K
What the payments were for
- Consulting fees$5152%
- Speaking & faculty fees$19,45669%
- Travel & lodging$5512%
- Food & beverage$7,58727%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $19,655 |
| Medicure Pharma Inc. | 5 | $1,900 |
| Kowa Pharmaceuticals America, Inc. | 6 | $1,544 |
| Novartis | 7 | $697 |
| Amarin Pharma, Inc. | 8 | $565 |
| Novo Nordisk | 8 | $540 |
| Ionis Pharmaceuticals, Inc. | 1 | $515 |
| Bayer | 8 | $290 |
| AstraZeneca | 5 | $274 |
| Esperion Therapeutics, Inc. | 3 | $264 |
| GSK | 2 | $242 |
| AbbVie | 2 | $203 |
| Regeneron | 2 | $198 |
| Regeneron Healthcare Solutions, Inc. | 2 | $191 |
| Lilly USA, LLC | 5 | $155 |
| Althera Pharmaceuticals LLC | 4 | $149 |
| Corcept Therapeutics | 2 | $143 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Rhythm Pharmaceuticals, Inc. | 1 | $115 |
| Teva Pharmaceuticals USA, Inc. | 1 | $102 |
| Merck | 1 | $62 |
| Johnson & Johnson | 1 | $59 |
| Biohaven Pharmaceuticals, Inc. | 1 | $51 |
| Abbott | 2 | $45 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,122 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 84 | $70,303 |
| FarxigaDapagliflozin Propanediol | 40 | $45,991 |
| MounjaroTirzepatide | 29 | $28,855 |
| JardianceEmpagliflozin | 23 | $27,842 |
| SynjardyEmpagliflozin/Metformin Hcl | 21 | $17,742 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $14,926 |
| Repatha SureclickEvolocumab | 21 | $11,611 |
| Ezetimibe | 228 | $9,303 |
| LivaloPitavastatin Calcium | 16 | $7,778 |
| Icosapent Ethyl | 13 | $5,969 |
| Rosuvastatin Calcium | 188 | $3,569 |
| Liothyronine Sodium | 70 | $3,120 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,020 |
| Niacin ErNiacin | 29 | $2,813 |
| Levothyroxine Sodium | 151 | $2,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $274 | $45,99140 claims |
| Lilly USA, LLCMounjaro | $155 | $28,85529 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $1,544 | $7,77816 claims |
| AbbVieSynthroid | $203 | $1,12515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Charles WoodwardEdmond$15K
- Darrel StoutEdmond$13K
- Christopher HayesEdmond$13K
- Jerimiah JohnsonEdmond$12K
- Alexander FrankOklahoma City$3.1M
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.